Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for SSc-PAH
NCT01086540Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2011
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2011; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH)
Beyond the preview
Go deeper on NCT01086540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086540.